Delphi Private Advisors buys $140,165 stake in Pfizer (PFE)

Pfizer (PFE) : Delphi Private Advisors scooped up 47 additional shares in Pfizer during the most recent quarter end , the firm said in a disclosure report filed with the SEC on Aug 11, 2016. The investment management firm now holds a total of 4,007 shares of Pfizer which is valued at $140,165.Pfizer makes up approximately 0.24% of Delphi Private Advisors’s portfolio.

Other Hedge Funds, Including , Lebenthal Asset Management boosted its stake in PFE in the latest quarter, The investment management firm added 152,550 additional shares and now holds a total of 169,280 shares of Pfizer which is valued at $5,921,414. Pfizer makes up approx 0.74% of Lebenthal Asset Management’s portfolio.Cable Hill Partners reduced its stake in PFE by selling 624 shares or 12.8% in the most recent quarter. The Hedge Fund company now holds 4,251 shares of PFE which is valued at $150,655. Pfizer makes up approx 0.10% of Cable Hill Partners’s portfolio.Reynders Mcveigh Capital Management boosted its stake in PFE in the latest quarter, The investment management firm added 4,945 additional shares and now holds a total of 53,372 shares of Pfizer which is valued at $1,891,504. Pfizer makes up approx 0.26% of Reynders Mcveigh Capital Management’s portfolio.Everett Harris Co Ca reduced its stake in PFE by selling 4,802 shares or 6.02% in the most recent quarter. The Hedge Fund company now holds 74,945 shares of PFE which is valued at $2,644,809. Pfizer makes up approx 0.09% of Everett Harris Co Ca’s portfolio.Moody National Bank Trust Division boosted its stake in PFE in the latest quarter, The investment management firm added 15,090 additional shares and now holds a total of 119,813 shares of Pfizer which is valued at $4,228,201. Pfizer makes up approx 0.24% of Moody National Bank Trust Division’s portfolio.

Pfizer opened for trading at $35 and hit $35.27 on the upside on Tuesday, eventually ending the session at $35.09, with a gain of 0.72% or 0.25 points. The heightened volatility saw the trading volume jump to 1,69,57,889 shares. Company has a market cap of $212,844 M.

On the company’s financial health, Pfizer reported $0.64 EPS for the quarter, beating the analyst consensus estimate by $ 0.02 according to the earnings call on Aug 2, 2016. Analyst had a consensus of $0.62. The company had revenue of $13147.00 million for the quarter, compared to analysts expectations of $13013.24 million. The company’s revenue was up 10.9% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.56 EPS.

Many Wall Street Analysts have commented on Pfizer. Shares were Reiterated by Jefferies on Jun 20, 2016 to “Buy” and Lowered the Price Target to $ 40 from a previous price target of $42 .

Pfizer Inc. is a global biopharmaceutical company. The Company is engaged in discovering developing and manufacturing of healthcare products. Its products include Lyrica the Prevnar family of products Enbrel Celebrex Lipitor Viagra Zyvox Sutent EpiPen Toviaz Tygacil Rapamune Xalkori Inlyta Norvasc BeneFIX Genotropin and Enbrel among others. It operates in three segments: Global Innovative Pharmaceutical segment (GIP) Global Vaccines Oncology and Consumer Healthcare segment (VOC) and Global Established Pharmaceutical segment (GEP). GIP is focused on developing registering and commercializing medications in therapeutic areas such as inflammation cardiovascular/metabolic neuroscience and pain rare diseases and women’s/men’s health. VOC focuses on the development and commercialization of vaccines and products for oncology and consumer healthcare. GEP includes its sterile injectable products and bio similar development portfolio. Its subsidiary is Hospira Inc.

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *